home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9605a.zip
/
M9650439.TXT
< prev
next >
Wrap
Text File
|
1996-03-09
|
2KB
|
37 lines
Document 0439
DOCN M9650439
TI Effects of isoniazid treatment on human lymphocyte proliferative
response, lymphocyte subsets and natural killer cell activity.
DT 9605
AU Ravn P; Linnet J; Klokker M; Pedersen BK; Department of Infectious
Diseases, Rigshospitalet, Copenhagen,; Denmark.
SO Immunopharmacology. 1995 Sep;30(3):247-53. Unique Identifier : AIDSLINE
MED/96128558
AB The effect of isoniazid on proliferative response, natural killer (NK)
cell activity and lymphocyte subset distribution of blood mononuclear
cells (BMNC) was investigated. To evaluate the effect of treatment with
isoniazid in pharmacologic concentrations, twenty healthy
HIV-seronegative volunteers were randomized into two groups: one group
received isoniazid tablets plus pyridoxin tablets once a day for 30
days, the other group received pyridoxin only. Blood samples were
collected on day 0 and day 30. Inhibition of the PHA-induced
proliferative response was demonstrated in lymphocyte cultures from
isoniazid-treated volunteers (p < 0.001). However, no effect was seen on
the IL-2- or antigen (PPD)-induced proliferative response or the NK cell
activity of isolated BMNC. Inhibition of the PHA-induced proliferative
response could not be related to changes in the distribution of CD3+,
CD4+, CD8+, CD14, or CD19+ lymphocyte subsets. The effects, in vitro,
were investigated by addition of isoniazid to cultures of BMNC isolated
from either HIV-seroposive or HIV-seronegative donors who did not
receive any treatment. We found that isoniazid did not influence the
mitogen- or antigen-stimulated proliferative response or the NK cell
activity.
DE Adult Antitubercular Agents/*PHARMACOLOGY Female Human
Isoniazid/*PHARMACOLOGY Killer Cells, Natural/*DRUG EFFECTS Lymphocyte
Subsets/*DRUG EFFECTS Lymphocyte Transformation/*DRUG EFFECTS Male
Pyridoxine/PHARMACOLOGY Support, Non-U.S. Gov't JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).